Hoatlin Lab: Difference between revisions
No edit summary |
|||
| (41 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
{{HoatlinLab}} | {{HoatlinLab}} | ||
<div style="padding: 15px; width: 710px; border: 5px solid #B3CD4E;"> | |||
<div style="padding: 1px; width: 700px; border: 3px solid #DDDDFF;"> | |||
<div style="border:1px solid orange;background-color:#FFFACD;padding:1px;"> | |||
---- | |||
'''Lab News''' | |||
;For news, follow the [http://twitter.com/HoatlinLab Hoatlin lab Twitter] | |||
</div> | |||
<br> | |||
Our laboratory is interested in understanding the molecular function of the Fanconi anemia (FA) protein network in context with other proteins that regulate or influence genomic stability. Fanconi anemia is a rare genetic disease that is typically associated with developmental abnormalities, bone marrow failure and increased risk of cancer. Because the majority of the FA proteins are unique with no significant homologies, we expect the results of our studies to shed new light on fundamental mechanisms that control the integrity of the human genome and influence cancer susceptibility. The FA pathway is part of a network of proteins that contains BRCA2 and two other recently identified FA genes (FANCN and FANCJ) that influence breast cancer susceptibility. Ultimately, insights into the mechanism of the FA/BRCA network of proteins will lead to an understanding of the underlying molecular defect in FA and may lead to more effective avenues of treatment for this devastating pediatric disease and cancer. | |||
We work in [[Hoatlin:Portland Oregon| Portland, Oregon]] at [http://www.ohsu.edu/ OHSU], in the [http://www.ohsu.edu/biochem/ Department of Biochemistry & Molecular Biology] and the [http://www.ohsucancer.com/ OHSU Knight Cancer Institute]. | |||
== | ==Bio for Maureen Hoatlin== | ||
Maureen Hoatlin is an Associate Professor of Biochemistry & Molecular Biology, and Molecular & Medical Genetics at Oregon Health & Science University (OHSU). After earning a B.S. degree in Chemistry from Old Dominion University, she was a project chemist at SRI International in Menlo Park, CA for two years, followed by six years as a research associate at Genentech, Inc. She received a Ph.D. at Oregon Health & Science University for graduate work focusing on the role of retroviruses in pathogenesis and hematopoietic cancers. She joined the faculty in Hematology & Medical Oncology at OHSU in 1993, and was a Visiting Scientist & Professor in the Department of Genetics at the Free University and Medical Center of Amsterdam in 1998 and in 2002. Dr. Hoatlin’s research is focused on identifying and analyzing the function of the proteins in the Fanconi Anemia/Breast Cancer (FA/BRCA) cancer susceptibility pathway. Her work has contributed to the discovery and characterization of ten novel human genes, many with critical but poorly understood roles in hematopoiesis, cancer susceptibility (AML and other cancers), and resistance to certain commonly-used chemotherapeutic drugs. Dr. Hoatlin’s lab pioneered a cell-free approach to analyze the function of the FA/BRCA pathway and recently received a patent for a novel small molecule inhibitor screen for identification of FA/BRCA pathway inhibitors and potential chemosensitizing compounds. | |||
Dr. Hoatlin has recently completed an MBA with a specialty on international business in Asia, as well a specialized UCSF course (ACDRS) on the drug development pipeline that focuses on preparation for future developments and changes in the global pharmaceutical sector. Dr. Hoatlin is a member of the strategic planning leadership for OHSU’s School of Medicine, the Hematologic Malignancies Program, advisory board member of the Oregon Translational Research and Development Institute, and founding co-chair of the OHSU Rare Disease Consortium. Dr. Hoatlin is interested in developing industry-academic partnerships aimed at using rare disease research to de-risk drug development. | |||
==Teaching Links== | |||
*Our lab's Fanconi Anemia antibodies are available from [http://www.novusbio.com Novus Biologicals] and by Millipore. | |||
[http://www.openwetware.org/wiki/Hoatlin:CONJ606/PMCB CONJ606/PMCB] | |||
[[Hoatlin:OHSU_Genetic_Mechanisms_Class| Genetic Mechanisms Class (CON662)]] | |||
[[Hoatlin: CSF|Med Students Fundamentals]] | |||
[ | ==Biochemistry Seminar Series== | ||
[http://www.openwetware.org/wiki/Hoatlin:BMB_seminar_series_2017-2018 Biochemistry Seminar Series and Combined Series Working Draft] | |||
==Classes of the past== | |||
[[BMCB625|Advanced Topics in Molecular Biology(BMB625)]] | [[BMCB625|Advanced Topics in Molecular Biology(BMB625)]] | ||
[[Hoatlin: | [http://openwetware.org/wiki/CANB_610 Advanced Topics in Cancer Biology (CANB 610)] | ||
[[Hoatlin:OHSU Replication, Recombination and Repair (R3) Club| OHSU DNA Replication, Recombination and Repair (R3) Club]]. | |||
==Who is Visiting Us?== | ==Who is Visiting Us?== | ||
Revision as of 11:56, 8 August 2017
Home Projects Team Papers Contact Us Protocols Collaborations News Reagent Requests secret back door Hoatlin Lab Twitter
|
We work in Portland, Oregon at OHSU, in the Department of Biochemistry & Molecular Biology and the OHSU Knight Cancer Institute. Bio for Maureen HoatlinMaureen Hoatlin is an Associate Professor of Biochemistry & Molecular Biology, and Molecular & Medical Genetics at Oregon Health & Science University (OHSU). After earning a B.S. degree in Chemistry from Old Dominion University, she was a project chemist at SRI International in Menlo Park, CA for two years, followed by six years as a research associate at Genentech, Inc. She received a Ph.D. at Oregon Health & Science University for graduate work focusing on the role of retroviruses in pathogenesis and hematopoietic cancers. She joined the faculty in Hematology & Medical Oncology at OHSU in 1993, and was a Visiting Scientist & Professor in the Department of Genetics at the Free University and Medical Center of Amsterdam in 1998 and in 2002. Dr. Hoatlin’s research is focused on identifying and analyzing the function of the proteins in the Fanconi Anemia/Breast Cancer (FA/BRCA) cancer susceptibility pathway. Her work has contributed to the discovery and characterization of ten novel human genes, many with critical but poorly understood roles in hematopoiesis, cancer susceptibility (AML and other cancers), and resistance to certain commonly-used chemotherapeutic drugs. Dr. Hoatlin’s lab pioneered a cell-free approach to analyze the function of the FA/BRCA pathway and recently received a patent for a novel small molecule inhibitor screen for identification of FA/BRCA pathway inhibitors and potential chemosensitizing compounds. Dr. Hoatlin has recently completed an MBA with a specialty on international business in Asia, as well a specialized UCSF course (ACDRS) on the drug development pipeline that focuses on preparation for future developments and changes in the global pharmaceutical sector. Dr. Hoatlin is a member of the strategic planning leadership for OHSU’s School of Medicine, the Hematologic Malignancies Program, advisory board member of the Oregon Translational Research and Development Institute, and founding co-chair of the OHSU Rare Disease Consortium. Dr. Hoatlin is interested in developing industry-academic partnerships aimed at using rare disease research to de-risk drug development. Teaching Links
Genetic Mechanisms Class (CON662) Biochemistry Seminar SeriesBiochemistry Seminar Series and Combined Series Working Draft Classes of the pastAdvanced Topics in Molecular Biology(BMB625) Advanced Topics in Cancer Biology (CANB 610) OHSU DNA Replication, Recombination and Repair (R3) Club. Who is Visiting Us?Who's visiting? <html>
<a href="http://clustrmaps.com/counter/maps.php?url=http://openwetware.org/wiki/Hoatlin_Lab" id="clustrMapsLink"><img src="http://clustrmaps.com/counter/index2.php?url=http://openwetware.org/wiki/Hoatlin_Lab" border=1 alt="Locations of visitors to this page"onError="this.onError=null; this.src='http://www.meetomatic.com/images/clustrmaps-back-soon.jpg'; document.getElementById('clustrMapsLink').href='http://clustrmaps.com/'">
</a>
</html>
Basic Wiki/OWW Links<wikionly> Recent changesList of abbreviations:
25 April 2024
24 April 2024
23 April 2024
22 April 2024
</wikionly> |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
